Profile data is unavailable for this security.
About the company
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. The Company’s proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).
- Revenue in USD (TTM)31.76m
- Net income in USD-18.40m
- Incorporated2001
- Employees62.00
- LocationMolecular Templates Inc9301 Amberglen Blvd Ste 100AUSTIN 78729-1153United StatesUSA
- Phone+1 (512) 896-1555
- Fax+1 (302) 655-5049
- Websitehttps://mtem.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Protext Mobility Inc | 750.00 | -2.21m | 8.79m | 4.00 | -- | -- | -- | 11,721.63 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
| BioRestorative Therapies Inc | 145.80k | -14.42m | 8.80m | 11.00 | -- | 0.5305 | -- | 60.36 | -3.54 | -3.54 | 0.0346 | 2.45 | 0.01 | -- | 8.26 | 13,254.55 | -99.26 | -199.86 | -104.68 | -334.04 | -- | -- | -9,887.16 | -19,887.03 | -- | -- | 0.00 | -- | 21.70 | 5.61 | 22.06 | -- | 67.77 | -- |
| eFFECTOR Therapeutics Inc | 0.00 | -34.63m | 9.13m | 14.00 | -- | 9.15 | -- | -- | -13.31 | -13.31 | 0.00 | 0.2119 | 0.00 | -- | -- | 0.00 | -141.18 | -- | -- | -- | -- | -- | -- | -- | -- | -17.12 | 0.9581 | -- | -100.00 | -- | -58.00 | -- | -- | -- |
| Notable Labs Ltd | 310.00k | -11.26m | 9.20m | 16.00 | -- | 0.6086 | -- | 29.67 | -3.08 | -3.08 | 0.0939 | 1.68 | 0.0126 | -- | -- | 19,375.00 | -45.79 | -52.02 | -56.70 | -62.09 | 36.45 | 60.19 | -3,633.55 | -3,636.93 | -- | -- | 0.0221 | -- | -52.89 | -11.93 | 65.13 | -- | -50.69 | -- |
| Ayala Pharmaceuticals Inc | 13.00k | -48.07m | 9.38m | 20.00 | -- | -- | -- | 721.49 | -7.46 | -7.46 | 0.0022 | -2.06 | -- | -- | -- | 650.00 | -- | -- | -- | -- | 0.00 | -- | -369,784.60 | -- | -- | -2.31 | -- | -- | -- | -- | -- | -- | -- | -- |
| Universe Pharmaceuticals Inc | 32.31m | -6.16m | 9.44m | 225.00 | -- | 0.2375 | -- | 0.2923 | -1.70 | -1.70 | 8.91 | 10.91 | 0.5727 | 7.93 | 2.50 | 143,594.40 | -10.92 | 5.31 | -14.34 | 7.07 | 31.93 | 46.26 | -19.08 | 6.25 | 2.43 | -28.05 | 0.1218 | 0.00 | -19.52 | 2.53 | 29.46 | -- | -21.17 | -- |
| Molecular Templates Inc | 31.76m | -18.40m | 9.55m | 62.00 | -- | 1.33 | -- | 0.3006 | -4.36 | -4.36 | 5.98 | 1.09 | 0.6014 | -- | 19.55 | 512,306.40 | -34.83 | -51.78 | -54.80 | -73.14 | -- | -- | -57.92 | -228.33 | -- | -52.11 | 0.00 | -- | 190.10 | 33.96 | 91.24 | -- | -48.87 | -- |
| Weed Inc | 0.00 | -31.55k | 9.63m | 2.00 | -- | 37.73 | 337.48 | -- | -0.0002 | -0.0002 | 0.00 | 0.0021 | 0.00 | -- | -- | 0.00 | -2.49 | -385.93 | -14.84 | -822.37 | -- | -- | -- | -- | -- | -16.98 | 0.3488 | -- | -- | -- | 97.93 | -- | -59.13 | -- |
| Mira Pharmaceuticals Inc | 0.00 | -12.36m | 9.68m | 3.00 | -- | 3.07 | -- | -- | -0.8276 | -0.8276 | 0.00 | 0.2136 | 0.00 | -- | -- | 0.00 | -587.64 | -- | -1,721.90 | -- | -- | -- | -- | -- | -- | -2.63 | 0.00 | -- | -- | -- | -69.77 | -- | -- | -- |
| Avalo Therapeutics Inc | 1.45m | -142.88m | 9.92m | 19.00 | -- | -- | -- | 6.84 | -318.69 | -318.69 | 3.02 | -97.75 | 0.0181 | -- | 3.25 | 76,315.79 | -178.64 | -99.64 | -- | -154.42 | 54.90 | 84.69 | -9,853.73 | -613.58 | -- | -0.2415 | -- | -- | -89.34 | -22.83 | 24.28 | -- | -22.48 | -- |
| Chromocell Therapeutics Corp | 0.00 | -7.38m | 10.09m | 4.00 | -- | -- | -- | -- | -1.28 | -1.28 | 0.00 | -1.12 | 0.00 | -- | -- | 0.00 | -9,746.19 | -- | -- | -- | -- | -- | -- | -- | -- | -13.23 | -- | -- | -- | -- | -200.20 | -- | -- | -- |
| BioNexus Gene Lab Corp | 9.77m | -2.63m | 10.14m | 30.00 | -- | 1.05 | -- | 1.04 | -0.1389 | -0.1389 | 0.6873 | 0.5466 | 0.9703 | 7.98 | 5.33 | -- | -26.11 | -3.83 | -31.86 | -5.02 | 13.61 | 14.55 | -26.91 | -3.04 | 4.24 | -186.19 | 0.00 | -- | -10.60 | 115.07 | -638.56 | -- | 30.40 | -- |
| Medical Marijuana Inc | -100.00bn | -100.00bn | 10.26m | -- | -- | 0.1104 | -- | -- | -- | -- | -- | 0.019 | -- | -- | -- | -- | -- | -22.66 | -- | -23.11 | -- | 70.58 | -- | -145.52 | 1.79 | -- | 0.0479 | -- | 26.30 | 39.07 | 141.59 | -- | -0.016 | -- |
| Vaxxinity Inc | 0.00 | -56.94m | 10.27m | 57.00 | -- | 0.7656 | -- | -- | -0.4499 | -0.4499 | 0.00 | 0.1058 | 0.00 | -- | -- | 0.00 | -75.56 | -- | -111.46 | -- | -- | -- | -- | -- | -- | -- | 0.5308 | -- | -- | -- | 24.31 | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to Molecular Templates Inc's reporting currency: US Dollar USD
50.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Bellevue Asset Management AGas of 31 Dec 2023 | 1.03m | 19.16% |
| BVF Partners LPas of 31 Dec 2023 | 532.04k | 9.90% |
| SilverArc Capital Management LLCas of 31 Dec 2023 | 354.61k | 6.60% |
| Adage Capital Management LPas of 31 Dec 2023 | 292.76k | 5.45% |
| Caxton Corp.as of 31 Dec 2023 | 136.87k | 2.55% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 125.61k | 2.34% |
| Monashee Investment Management LLCas of 31 Dec 2023 | 121.84k | 2.27% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 39.64k | 0.74% |
| Geode Capital Management LLCas of 31 Dec 2023 | 36.71k | 0.68% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 23.65k | 0.44% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
